Clinical Trials Sponsored by Hunan Kelun Pharmaceutical Co., Ltd.

Total 3815 results

Hunan Kelun Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Gefitinib Tablets Under Fed Conditions

Healthy
Hunan Kelun Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions

Bioequivalence Study
Sichuan Kelun Pharmaceutical Research Institute...

Not yet recruiting

SKB410 for Injection in Solid Tumors

Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

A Study of A166 in Patients With Advanced Solid Malignant Tumors

Breast Cancer

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Cancer

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Active, not recruiting

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Non-small Cell Lung Cancer

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Triple-negative Breast Cancer and HR+/HER2- BC

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Active, not recruiting

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Recurrent or Metastatic

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Completed

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Recurrent or Metastatic

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Completed

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Classical Hodgkin Lymphoma

China
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

Selected Subjects With Advanced Solid Tumors

China
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Sichuan Kelun Pharmaceutical Research Institute...

Not yet recruiting

A Study of KL130008 in Adults With Severe Alopecia Areata

Alopecia Areata

China
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

A Study of SKB315 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

Metastatic Colorectal Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...

Not yet recruiting

A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Metastatic Breast Cancer
Sichuan Kelun Pharmaceutical Research Institute...

Not yet recruiting

A Study of KL340399 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Metastatic Colorectal Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...

Enrolling by invitation

A Study of KL590586 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Henan Cancer Hospital
Qilu Pharmaceutical Co., Ltd.; Beijing Biostar Pharmaceuticals Co., Ltd.

Not yet recruiting

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

HER-2 Negative Breast Cancer
Sichuan Kelun Pharmaceutical Research Institute...
307 Hospital of PLA

Unknown

Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
Kuhnil Pharmaceutical Co., Ltd.
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients

Sleep Initiation and Maintenance Disorders

Korea, Republic of
Ahn-Gook Pharmaceuticals Co.,Ltd
Daehwa Pharmaceutical Co., Ltd.

Not yet recruiting

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

Essential Hypertension
Kuhnil Pharmaceutical Co., Ltd.
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients

Sleep Initiation and Maintenance Disorders

Korea, Republic of
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Unknown

An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

Type 2 Diabetes Mellitus

United States
Klus Pharma Inc.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Tasly GeneNet Pharmaceuticals Co., Ltd

Recruiting

A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Charcot-Marie-Tooth Type 1A

China
Hunan Cancer Hospital
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

Hepatocellular Carcinoma | Immune Checkpoint Inhibitors

China
Ascletis Pharmaceuticals Co., Ltd.
Hunan Provincial People's Hospital

Completed

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

Healthy

China
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Ono Pharmaceutical Co. Ltd
Kyorin Pharmaceutical Co.,Ltd

Completed

Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder

Overactive Bladder

Japan
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

China
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Refractory

China
Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Completed

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

Lymphoma, Non-Hodgkin

United States
Novartis Pharmaceuticals
Ono Pharmaceutical Co. Ltd

Completed

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Alzheimer's Disease

Japan
Novartis Pharmaceuticals
Ono Pharmaceutical Co. Ltd

Completed

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Alzheimer's Disease

Japan
Novartis Pharmaceuticals
Ono Pharmaceutical Co. Ltd

Completed

Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

China
Henan Cancer Hospital
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Non-small Cell Lung Cancer

China
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Pharmacokinetics of Probucol and Cilostazol

Healthy

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects. (OPS-2071Ph1)

Healthy

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

Tourette's Disorder | Chronic Motor or Vocal Tic Disorder

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Unknown

Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients

Oral Mucositis

Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Taiwan, Korea, Republic of, Japan
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

Solid Tumor

Korea, Republic of

Clinical Trials Sponsored by Hunan Kelun Pharmaceutical Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations